AVITA Medical’s (RCEL) Buy Rating Reiterated at D. Boral Capital

AVITA Medical (NASDAQ:RCEL)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research report issued on Friday,Benzinga reports. They currently have a $25.00 price target on the stock. D. Boral Capital’s target price indicates a potential upside of 184.74% from the stock’s current price.

Other research analysts have also issued research reports about the company. Lake Street Capital cut their price target on AVITA Medical from $20.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Piper Sandler reaffirmed a “neutral” rating and issued a $12.00 target price (up from $9.00) on shares of AVITA Medical in a report on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price target on shares of AVITA Medical in a research report on Tuesday, December 24th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

AVITA Medical Trading Up 2.0 %

NASDAQ RCEL opened at $8.78 on Friday. The firm’s fifty day moving average price is $10.74 and its 200 day moving average price is $10.58. AVITA Medical has a 12 month low of $7.51 and a 12 month high of $18.93. The company has a debt-to-equity ratio of 3.48, a current ratio of 3.73 and a quick ratio of 3.37. The company has a market capitalization of $230.21 million, a price-to-earnings ratio of -3.94 and a beta of 1.55.

AVITA Medical (NASDAQ:RCEL) last released its quarterly earnings data on Thursday, February 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.14). AVITA Medical had a negative net margin of 95.47% and a negative return on equity of 194.69%. On average, sell-side analysts expect that AVITA Medical will post -2.38 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of RCEL. Huntington National Bank purchased a new stake in shares of AVITA Medical during the third quarter worth approximately $32,000. FMR LLC raised its position in AVITA Medical by 126.9% during the 3rd quarter. FMR LLC now owns 4,248 shares of the company’s stock worth $46,000 after buying an additional 2,376 shares during the last quarter. Quest Partners LLC lifted its stake in shares of AVITA Medical by 269.4% in the 3rd quarter. Quest Partners LLC now owns 7,520 shares of the company’s stock worth $81,000 after acquiring an additional 5,484 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of AVITA Medical in the 2nd quarter worth $86,000. Finally, Russell Investments Group Ltd. increased its stake in shares of AVITA Medical by 48.0% during the fourth quarter. Russell Investments Group Ltd. now owns 7,164 shares of the company’s stock worth $92,000 after acquiring an additional 2,324 shares during the period. 27.66% of the stock is currently owned by hedge funds and other institutional investors.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.